Skip To Main Content
Hammel Pascal on Muck Rack

Hammel Pascal

As seen in: Annals of Oncology
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile
Back to Hammel Pascal’s profile

Articles by Hammel Pascal

P-272The international, open-label, multicenter phase 2 LAPACT trial of nab-paclitaxel (nab-P) plus gemcitabine (Gem) for patients with locally advanced pancreatic cancer (LAPC)

|
By Hammel Pascal, Hôpital Beaujon, Lacy Jill, Portales Fabienne, Sobrero Alberto
| Annals of Oncology Verified
Introduction: Efficacious systemic therapies for LAPC may be associated with improved local disease control and overall survival (OS). The phase 3 MPACT trial in patients with previously untreated metastatic PC demonstrated longer OS (median, 8.7 vs 6.6 months; hazard ratio 0.72; P < 0.001) and an ≈ 3-fold greater shrinkage of primary pancreatic tumors with nab-P + Gem vs Gem alone (−22.15% vs −7.02%), which suggests the potential for improved local PC control with this combination.
Open in Who Shared Issue with article?
Show More